Tekmira's Partner NCI Presents Promising Data on Liver Cancer Treatment
Posted on: Tuesday, 9 September 2008, 09:00 CDT
Tekmira Pharmaceuticals has announced that one of its collaborators, the National Cancer Institute, has presented promising preclinical data treating liver cancer using small interfering RNA enabled by the company's stable nucleic acid-lipid particles delivery technology.
Scientists at the National Cancer Institute's (NCI's) Laboratory of Experimental Carcinogenesis and the surgery branch of the NCI worked in collaboration with Tekmira scientists to develop small interfering RNA (siRNA) to silence the CSN5 gene.
The CSN5 siRNA delivered systemically using Tekmira's stable nucleic acid-lipid particles (SNALP) technology resulted in a significant reduction in tumor burden in human hepatocellular carcinoma (HCC) tumor bearing mice, said Tekmira.
According to the company, CSN5 could represent a novel therapeutic target to treat HCC. Down regulation of CSN5 using siRNA increases apoptosis (programmed cell death) by restoring levels of tumor suppressor proteins p53 and p27. Silencing the CSN5 gene has also been shown to decrease a certain population of cells thought to be cancer stem cells.
Tekmira and NCI are continuing to collaborate on identifying novel cancer genes and demonstrating anti-tumor activity by silencing these genes through RNA interference.
Mark Murray, Tekmira's president and CEO, said: "We have had a very successful collaboration with NCI over the past two years. By combining their expertise in identifying novel cancer genes and our expertise in designing and delivering siRNA molecules, we have been able to generate this promising data targeting the CSN5 gene."
Source: Datamonitor
Related Articles
- Cancer Metabolism Discovery Uncovers New Role Of IDH1 Gene Mutation In Brain Cancer
- ACMG Joins Lawsuit Challenging Patents on Breast Cancer Genes; Genes Are Naturally Occurring Substances and Should Not Be Patented, Says American College of Medical Genetics
- Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
- GENEART Presents the Industrial Production of Genes, Gene Li-Braries and Genomes at the Biotechnica
- Lentigen Corporation Receives Grant From NIH to Evaluate the Use of Lentiviral-Engineered T-Cells for Cancer Immunotherapy Directed Against Key Tumor Antigen
- Interfering RNA Silences Genes in 'Slippery' Immune Cells -- Novel Lab Technique Expands Researchers' Toolbox --
- Pro-Pharmaceuticals' Phase I Data Show DAVANAT/5-FU Well-Tolerated in Cancer Patients With Advanced Solid Tumors
- Evolution of a RNA Polymerase Gene Family in Silene (Caryophyllaceae)-Incomplete Concerted Evolution and Topological Congruence Among Paralogues
- New Cancer Fight Hopes ; Success for Ulster Team in Gene Therapy Tests
- Cancer Stem Cell Found for Tumors
 |
 |
User Comments (1)
| 1. |
Posted by Frank Cook on 07/01/2009, 10:30 Thank you for your cogent thoughts on cancer treatment; this is an important topic of conversation, and I found your contributions provocative and insightful. The organization I work for, the Pacific Northwest Foundation, is devoted to researching alternative modes of healing for a variety of illnesses, including cancer. I wanted to share with you a video presentation of a case study we conducted some years ago about an elderly woman with terminal cancer who, through a variety of methods, was able to eliminate her tumors. The link to the presentation is http://pnf.org/html/cancer.html. I'd like to thank you so much for your contribution to the subject of cancer treatment, and hope you will find the case study above helpful in your continued exploration into the subject. |
RSS Feeds